Federal Court of Appeal requires PMPRB to re-determine whether patent ‘pertains to’ Galderma’s DIFFERIN

Published date11 July 2019
Subject MatterPatents,Appeals,Judicial Review,Standard of Review,Claim Construction,Remand,Reasonableness Factors,Pharmaceutical Patents,Canada,Agency Deference,Patent Expiration,Patented Medicines,Patented Medicine Prices Review Board (PMPRB)
AuthorUrszula Wojtyra
Law FirmSmart & Biggar

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT